PTC Therapeutics (PTCT) Marked As A Dead Cat Bounce Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified PTC Therapeutics ( PTCT) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified PTC Therapeutics as such a stock due to the following factors:

  • PTCT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $47.3 million.
  • PTCT has traded 57,436 shares today.
  • PTCT is up 5.4% today.
  • PTCT was down 12.7% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in PTCT with the Ticky from Trade-Ideas. See the FREE profile for PTCT NOW at Trade-Ideas

More details on PTCT:

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. Currently there are 8 analysts that rate PTC Therapeutics a buy, no analysts rate it a sell, and 1 rates it a hold.

The average volume for PTC Therapeutics has been 696,800 shares per day over the past 30 days. PTC has a market cap of $2.0 billion and is part of the health care sector and drugs industry. Shares are up 15.6% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

No Good Stock Left Behind: Cramer's 'Mad Money' Recap (Tuesday 7/25/17)

Hertz Global Holdings, Honeywell, PetMed Express, Allergan: 'Mad Money' Lightning Round

Biotech Movers: Albany Molecular Shares Soar on Sale to PE Firms

Biotech Premarket Movers: Seres, PTC, Inovio

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle